2-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-1,2-dihydro-3H-1,2,4-triazol-3-one | 844904-76-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-1,2-dihydro-3H-1,2,4-triazol-3-one
• 英文别名: 2-[3-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]phenyl]-4H-1,2,4-triazol-3-one
• CAS: 844904-76-3
• 化学式: C₂₄H₂₆N₆O
• 分子量: 414.51
• InChiKey: FQYSBQVEJOAOKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS<br/>[FR] DERIVES DE QUINOLINE ET DE QUINAZOLINE PRESENTANT UNE AFFINITE VIS-A-VIS DES RECEPTEURS DU TYPE 5HT1
  申请人：GLAXO GROUP LTD

  公开号：WO2005014552A1

  公开（公告）日：2005-02-17

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

  提供了式(I)的化合物及其药用盐：其中R1、m、X、R2、n、W、p、Y、Z、R3、R4、R5和q的含义如描述中所定义。还公开了制备方法以及在治疗中的用途，特别是用于抑郁症或焦虑等中枢神经系统疾病。
• Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
  申请人：Bergauer Markus

  公开号：US20060229312A1

  公开（公告）日：2006-10-12

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R 1 , m, X, R 2 , n, W, p, Y, Z, R 3 , R 4 , R 5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

  提供式(I)的化合物和药学上可接受的盐：其中R1，m，X，R2，n，W，p，Y，Z，R3，R4，R5和q的含义如描述中所定义。还公开了制备方法以及在治疗中的用途，特别是用于中枢神经系统疾病，如抑郁症或焦虑症。
• QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS
  申请人：Bergauer Markus

  公开号：US20070167423A1

  公开（公告）日：2007-07-19

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R 1 , m, X, R 2 , n, W, p, Y, Z, R 3 , R 4 , R 5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

  提供了式(I)的化合物及其药学上可接受的盐： 其中，R1、m、X、R2、n、W、p、Y、Z、R3、R4、R5和q的含义如描述中定义的那样。还公开了其制备方法和在治疗中的用途，特别是用于中枢神经系统疾病如抑郁症或焦虑症。
• Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors
  申请人：Bergauer Markus

  公开号：US20100204273A1

  公开（公告）日：2010-08-12

  Disclosed are methods for use of compounds of formula (I) in the treatment of CNS disorders such as dysthymia, schizophrenia, panic disorder, obsessive compulsive disorder, post-traumatic stress disorder, pain, and memory disorders: wherein R 1 , m, X, R 2 , n, W, p, Y, Z, R 3 , R 4 , R 5 and q have the meanings as defined in the description.

  本发明揭示了使用式（I）化合物治疗中枢神经系统疾病，如心境不良、精神分裂症、惊恐障碍、强迫症、创伤后应激障碍、疼痛和记忆障碍的方法：其中R1，m，X，R2，n，W，p，Y，Z，R3，R4，R5和q的含义如描述中定义的那样。
• Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
  申请人：GLAXO GROUP LIMITED

  公开号：EP1876174B1

  公开（公告）日：2009-11-11